Published in Pharmacol Biochem Behav on February 11, 2008
Key factors in the discovery and development of new antiepileptic drugs. Nat Rev Drug Discov (2010) 2.22
Rhythm and blues: animal models of epilepsy and depression comorbidity. Biochem Pharmacol (2012) 0.85
Targeting the BH3-interacting domain death agonist to develop mechanistically unique antidepressants. Mol Psychiatry (2011) 0.79
Key factors in the discovery and development of new antiepileptic drugs. Nat Rev Drug Discov (2010) 2.22
Antiepileptic drug therapy: does mechanism of action matter? Epilepsy Behav (2011) 2.20
Anticonvulsant activity of hydrazones, Schiff and Mannich bases of isatin derivatives. Eur J Pharm Sci (2002) 2.15
A role of SCN9A in human epilepsies, as a cause of febrile seizures and as a potential modifier of Dravet syndrome. PLoS Genet (2009) 2.12
Models for epilepsy and epileptogenesis: report from the NIH workshop, Bethesda, Maryland. Epilepsia (2002) 1.91
Acetoacetate, acetone, and dibenzylamine (a contaminant in l-(+)-beta-hydroxybutyrate) exhibit direct anticonvulsant actions in vivo. Epilepsia (2002) 1.82
Synthesis and anticonvulsant activity of enaminones. 4. Investigations on isoxazole derivatives. Eur J Med Chem (2002) 1.63
Identification of new epilepsy treatments: issues in preclinical methodology. Epilepsia (2012) 1.45
Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res (2010) 1.35
Mouse models of human KCNQ2 and KCNQ3 mutations for benign familial neonatal convulsions show seizures and neuronal plasticity without synaptic reorganization. J Physiol (2008) 1.35
Seizures following picornavirus infection. Epilepsia (2008) 1.31
Anticonvulsant activity of Schiff bases of isatin derivatives. Acta Pharm (2004) 1.27
Innate but not adaptive immune responses contribute to behavioral seizures following viral infection. Epilepsia (2009) 1.26
Comparative anticonvulsant efficacy in the corneal kindled mouse model of partial epilepsy: Correlation with other seizure and epilepsy models. Epilepsy Res (2010) 1.25
A spontaneous mutation involving Kcnq2 (Kv7.2) reduces M-current density and spike frequency adaptation in mouse CA1 neurons. J Neurosci (2006) 1.24
Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI). Epilepsy Res (2012) 1.24
Discovery of antiepileptic drugs. Neurotherapeutics (2007) 1.24
Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes. J Clin Pharmacol (2005) 1.23
Interleukin-6, produced by resident cells of the central nervous system and infiltrating cells, contributes to the development of seizures following viral infection. J Virol (2011) 1.22
Cytotoxic 5-aryl-1-(4-nitrophenyl)-3-oxo-1,4-pentadienes mounted on alicyclic scaffolds. Eur J Med Chem (2006) 1.21
The cytotoxic properties and preferential toxicity to tumour cells displayed by some 2,4-bis(benzylidene)-8-methyl-8-azabicyclo[3.2.1] octan-3-ones and 3,5-bis(benzylidene)-1-methyl-4-piperidones. Eur J Med Chem (2008) 1.20
Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy. Epilepsy Res (2007) 1.20
Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res (2008) 1.20
Translational aspects of pharmacological research into anxiety disorders: the stress-induced hyperthermia (SIH) paradigm. Eur J Pharmacol (2008) 1.19
Synthesis of isatin semicarbazones as novel anticonvulsants--role of hydrogen bonding. J Pharm Pharm Sci (2003) 1.18
Spontaneous deletion of epilepsy gene orthologs in a mutant mouse with a low electroconvulsive threshold. Hum Mol Genet (2003) 1.17
Synthesis of some 3-(arylalkylthio)-4-alkyl/aryl-5-(4-aminophenyl)-4H-1,2,4-triazole derivatives and their anticonvulsant activity. Farmaco (2004) 1.15
Mechanisms of action of antiepileptic drugs. Int Rev Neurobiol (2007) 1.14
Dissociation between duration of action in the forced swim test in mice and nicotinic acetylcholine receptor occupancy with sazetidine, varenicline, and 5-I-A85380. Psychopharmacology (Berl) (2011) 1.14
A rat brain slice preparation for characterizing both thalamostriatal and corticostriatal afferents. J Neurosci Methods (2006) 1.14
Development of postinfection epilepsy after Theiler's virus infection of C57BL/6 mice. J Neuropathol Exp Neurol (2010) 1.14
Design, synthesis and evaluation of novel hydroxyamides as orally available anticonvulsants. Bioorg Med Chem (2004) 1.13
Antagonists of GLU(K5)-containing kainate receptors prevent pilocarpine-induced limbic seizures. Nat Neurosci (2002) 1.12
Effects of the anticonvulsant retigabine on cultured cortical neurons: changes in electroresponsive properties and synaptic transmission. Mol Pharmacol (2002) 1.11
Neuronal and non-neuronal GABA transporters as targets for antiepileptic drugs. Pharmacol Ther (2009) 1.10
Theiler's virus infection chronically alters seizure susceptibility. Epilepsia (2009) 1.05
Antiseizure activity of novel gamma-aminobutyric acid (A) receptor subtype-selective benzodiazepine analogues in mice and rat models. J Med Chem (2009) 1.05
Cytotoxic analogues of 2,6-bis(arylidene)cyclohexanones. Eur J Med Chem (2003) 1.04
Sub-optimal performance in the 5-choice serial reaction time task in rats was sensitive to methylphenidate, atomoxetine and d-amphetamine, but unaffected by the COMT inhibitor tolcapone. Neurosci Res (2010) 1.04
Development and characterization of novel derivatives of the antiepileptic drug lacosamide that exhibit far greater enhancement in slow inactivation of voltage-gated sodium channels. ACS Chem Neurosci (2011) 1.02
Design, synthesis, and characterization of high-affinity, systemically-active galanin analogues with potent anticonvulsant activities. J Med Chem (2008) 1.02
The spectrum of anticonvulsant efficacy of retigabine (ezogabine) in animal models: implications for clinical use. Epilepsia (2012) 1.01
N-Aroyl-3,5-bis(benzylidene)-4-piperidones: a novel class of antimycobacterial agents. Bioorg Med Chem (2008) 1.00
Cytotoxic 1,3-diarylidene-2-tetralones and related compounds. Eur J Med Chem (2002) 0.99
Differential effects of the anticonvulsant topiramate on neurobehavioral and histological outcomes following traumatic brain injury in rats. J Neurotrauma (2004) 0.99
Correlation analysis between anticonvulsant ED50 values of antiepileptic drugs in mice and rats and their therapeutic doses and plasma levels. Epilepsy Behav (2004) 0.99
Activities of α-asarone in various animal seizure models and in biochemical assays might be essentially accounted for by antioxidant properties. Neurosci Res (2010) 0.99
Differences in excitatory transmission between thalamic and cortical afferents to single spiny efferent neurons of rat dorsal striatum. Eur J Neurosci (2008) 0.98
The high-affinity nAChR partial agonists varenicline and sazetidine-A exhibit reinforcing properties in rats. Prog Neuropsychopharmacol Biol Psychiatry (2010) 0.98
Rapid, computer vision-enabled murine screening system identifies neuropharmacological potential of two new mechanisms. Front Neurosci (2011) 0.98
Evidence for functionally distinct synaptic NMDA receptors in ventromedial versus dorsolateral striatum. J Neurophysiol (2003) 0.98
Application of predictive QSAR models to database mining: identification and experimental validation of novel anticonvulsant compounds. J Med Chem (2004) 0.96
Issues related to development of new antiseizure treatments. Epilepsia (2013) 0.96
Effect of lamotrigine treatment on epileptogenesis: an experimental study in rat. Epilepsy Res (2004) 0.95
Synaptic and extrasynaptic GABA transporters as targets for anti-epileptic drugs. J Neurochem (2009) 0.95
GABA transporters as drug targets for modulation of GABAergic activity. Biochem Pharmacol (2004) 0.95
Design & synthesis of N'-[substituted] pyridine-4-carbohydrazides as potential anticonvulsant agents. Eur J Med Chem (2010) 0.95
Role for complement in the development of seizures following acute viral infection. J Virol (2010) 0.94
Conantokin-L, a new NMDA receptor antagonist: determinants for anticonvulsant potency. Epilepsy Res (2002) 0.94
Development of new treatment approaches for epilepsy: unmet needs and opportunities. Epilepsia (2013) 0.94
Antiseizure drugs differentially modulate θ-burst induced long-term potentiation in C57BL/6 mice. Epilepsia (2014) 0.94
Psychostimulant-like discriminative stimulus and locomotor sensitization properties of the wake-promoting agent modafinil in rodents. Pharmacol Biochem Behav (2010) 0.94
Structural requirements for a lipoamino acid in modulating the anticonvulsant activities of systemically active galanin analogues. J Med Chem (2009) 0.94
Antiepileptic popular ketogenic diet: emerging twists in an ancient story. Prog Neurobiol (2005) 0.93
Mice carrying the szt1 mutation exhibit increased seizure susceptibility and altered sensitivity to compounds acting at the m-channel. Epilepsia (2004) 0.93
Design and evaluation of affinity labels of functionalized amino acid anticonvulsants. J Med Chem (2002) 0.93
The anticonvulsant profile of rufinamide (CGP 33101) in rodent seizure models. Epilepsia (2008) 0.92
A pharmacophore derived phenytoin analogue with increased affinity for slow inactivated sodium channels exhibits a desired anticonvulsant profile. Neuropharmacology (2006) 0.92
SAHA enhances synaptic function and plasticity in vitro but has limited brain availability in vivo and does not impact cognition. PLoS One (2013) 0.91
Conantokins: peptide antagonists of NMDA receptors. Curr Med Chem (2004) 0.91
Once initiated, viral encephalitis-induced seizures are consistent no matter the treatment or lack of interleukin-6. J Neurovirol (2011) 0.91
The effect of CGX-1007 and CI-1041, novel NMDA receptor antagonists, on NMDA receptor-mediated EPSCs. Epilepsy Res (2004) 0.91
Synthesis and anticonvulsant activities of (R)-N-(4'-substituted)benzyl 2-acetamido-3-methoxypropionamides. J Med Chem (2010) 0.91
Glycosylated neurotensin analogues exhibit sub-picomolar anticonvulsant potency in a pharmacoresistant model of epilepsy. ChemMedChem (2009) 0.91
The expression of kainate receptor subunits in hippocampal astrocytes after experimentally induced status epilepticus. J Neuropathol Exp Neurol (2013) 0.90
The cyclooxygenase-2 inhibitor GW406381X [2-(4-ethoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-pyrazolo[1,5-b]pyridazine] is effective in animal models of neuropathic pain and central sensitization. J Pharmacol Exp Ther (2004) 0.90
c-Fos immunohistochemical mapping of the audiogenic seizure network and tonotopic neuronal hyperexcitability in the inferior colliculus of the Frings mouse. Epilepsy Res (2004) 0.90
Correlations between cytotoxicity and topography of some 2-arylidenebenzocycloalkanones determined by X-ray crystallography. J Med Chem (2002) 0.90
Lacosamide isothiocyanate-based agents: novel agents to target and identify lacosamide receptors. J Med Chem (2009) 0.89
Design, synthesis and potential 6 Hz psychomotor seizure test activity of some novel 2-(substituted)-3-{[substituted]amino}quinazolin-4(3H)-one. Eur J Med Chem (2011) 0.89
A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage. Epilepsia (2011) 0.88
Synthesis and anticonvulsant activities of N-benzyl (2R)-2-acetamido-3-oxysubstituted propionamide derivatives. Bioorg Med Chem (2008) 0.87
Altered learning and Arc-regulated consolidation of learning in striatum by methamphetamine-induced neurotoxicity. Neuropsychopharmacology (2011) 0.87
Phenytoin- and carbamazepine-resistant spontaneous bursting in rat entorhinal cortex is blocked by retigabine in vitro. Epilepsy Res (2007) 0.87